Market closed · Next open: Tuesday 9:30 AM ET
Last update: Sep 14, 2026, 6:10 PM ET
Hims & Hers Health, Inc.
$28.81 4.73% today
Market Closed

Why Hims & Hers Health, Inc. (HIMS) stock moved

Updated Sep 15, 2026

Hims & Hers Health, Inc. (HIMS) shares rose 4.7% to $28.81 as of September 15, 2026, a moderate gain from the prior close of $27.51. BestStocks flagged the session as a major change for HIMS. The move is tied to price move up. Below, we break down what changed for HIMS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

HIMS climbed 4.7% to $28.81

HIMS rose 4.7% in its latest session, moving from $27.51 to $28.81.

Material / EarningsLow confidence
Rel. volume
0.7×
Below Avg
Vs peers
No comparable peers
Market cap
$6.4B
New York Stock Exchange
Analyst target
$32
+11.7% vs price
Price chart
Aug 17 – Sep 15
EVVVVEE$27$31$34Aug 17Aug 24Aug 31Sep 8Sep 15
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Hims & Hers Health, Inc. investors

For Hims & Hers Health, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 4.7% session move. Weighing against that: HIMS fell 2.84% to $27.37 amid a combination of broader market weakness—driven by U.S.-Iran tensions, rising Treasury yields, and surging oil prices—alongside legal and regulatory headwinds including shareholder class-action lawsuits and an unresolved FTC complaint over deceptive billing and data-sharing practices, per the web catalyst synthesis; Hims & Hers Health (HIMS) declined 6.41% to $29.63 intraday, cited by Google's AI Overview as linked to content on finance.yahoo.com covering the stock's move on 2026-08-28. Wall Street's consensus price target sits at $32.17, implying +11.7% upside from $28.81. BestStocks rates the overall signal quality low (55/100). With earnings roughly 55 days out, the next report is the most likely near-term test of the move.

HIMS price reaction

HIMS last traded at $28.81, up $1.30 (+4.73%) from the previous close of $27.51. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $27.39 and $33.78, and it currently sits about 22% of the way up that band.

Bullish and bearish analyst opinions on Hims & Hers Health, Inc. (HIMS)

The consensus analyst price target on Hims & Hers Health, Inc. (HIMS) is $32.17, 11.7% above the recent $28.81. Over the past 90 days analysts logged 0 upgrades, 14 maintains, and 0 downgrades. Here is how the bullish and bearish cases on HIMS line up.

The bullish case

  • Wall Street's consensus price target of $32.17 implies +11.7% upside from $28.81.
  • The Street's most bullish target is $42.00 (+45.8%).
  • Material positive event.
  • Positive 4.7% session move.
  • Hims & Hers Health bounced +6.92% to $31.89 on reports of a potential partnership with weight-loss drug maker Novo Nordisk to distribute branded products on its platform, according to web sources.

The bearish case

  • The most bearish analyst target is $24.50 (-15.0%).
  • HIMS fell 2.84% to $27.37 amid a combination of broader market weakness—driven by U.S.-Iran tensions, rising Treasury yields, and surging oil prices—alongside legal and regulatory headwinds including shareholder class-action lawsuits and an unresolved FTC complaint over deceptive billing and data-sharing practices, per the web catalyst synthesis.
  • Hims & Hers Health (HIMS) declined 6.41% to $29.63 intraday, cited by Google's AI Overview as linked to content on finance.yahoo.com covering the stock's move on 2026-08-28.
  • Hims & Hers shares fell 6.05% to $29.83, continuing a sharp year-to-date decline of 15.9% (per Yahoo Finance, Apr 29, 2026).
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Sep 15, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $32+11.7%
= 14 maintains
Truist Securities maintained Hold · 2026-08-24
SEC filings watch
10-Q2026-08-10
Quarterly financial results
medium
8-K2026-08-10
Material event — review for impact
high
8-K2026-07-17
Material event — review for impact
high
8-K2026-07-01
Material event — review for impact
high
Peer context
HIMS+4.7%

Previous notable changes for HIMS

Risk2026-09-09-1.0%via investing.com
HIMS fell 2.84% to $27.37 amid a combination of broader market weakness—driven by U.S.-Iran tensions, rising Treasury yields, and surging oil prices—alongside legal and regulatory headwinds including shareholder class-action lawsuits and an unresolved FTC complaint over deceptive billing and data-sharing practices, per the web catalyst synthesis. Competitive pressures in the GLP-1 and weight-management telehealth space from rivals like Ro and Amazon further weighed on sentiment. Volume was light at 0.56x the time-adjusted average, suggesting subdued participation early in the session.
Risk2026-08-28-8.9%via Yahoo Finance
Hims & Hers Health (HIMS) declined 6.41% to $29.63 intraday, cited by Google's AI Overview as linked to content on finance.yahoo.com covering the stock's move on 2026-08-28. The specific driver remains unclear from available evidence; Yahoo Finance articles addressing the move were identified but detailed content was not accessible to confirm the catalyst.
Activity2026-08-27+6.1%via Yahoo Finance
Hims & Hers Health bounced +6.92% to $31.89 on reports of a potential partnership with weight-loss drug maker Novo Nordisk to distribute branded products on its platform, according to web sources. The move also included short covering as traders repositioned following recent headwinds from Visa's acquirer monitoring program and FTC inquiry. Trading volume of 7.1 million shares ran 0.55x average for this time of day.
Risk2026-08-26-6.0%via Yahoo Finance
Hims & Hers shares fell 6.05% to $29.83, continuing a sharp year-to-date decline of 15.9% (per Yahoo Finance, Apr 29, 2026). The stock is trading 57.6% below its 52-week high of $66.18. Trading volume of 6.5M shares was below the 270-minute average (0.66x ratio), suggesting modest institutional participation in the decline.
Upcoming catalysts & outlook
Next earnings
2026-11-09 (est.)
in 55 days
Thesis shift
Neutral / Mixed
bullish signal
Risk level
High
from change events

Frequently asked questions about HIMS

Why did Hims & Hers Health, Inc. (HIMS) stock move?

HIMS rose 4.7% to $28.81. No single company-specific catalyst was confirmed during the move window, and it looks technical.

How much did HIMS stock rise?

HIMS gained 4.73% ($1.30) versus the prior close of $27.51, last trading at $28.81 on 0.7× average volume.

When is Hims & Hers Health, Inc.'s next earnings date?

HIMS's next earnings report is estimated for 2026-11-09 — about 55 days away.

What is the analyst price target for HIMS?

The consensus analyst price target for HIMS is $32.17, about 11.7% above the current $28.81. Over the past 90 days, analysts recorded 0 upgrades, 14 maintains, and 0 downgrades.

How BestStocks tracks HIMS

This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for HIMS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 15, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataFMP earnings & estimatesSEC EDGAR filingsAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.